Genentech
A Member of the Roche Group

Notice Regarding Availability of 340B Pricing for Sole Community Hospitals, Rural Referral Centers, Critical Access Hospitals, and Free Standing Cancer Hospitals for the Genentech Product Perjeta - 14 ml (420 mg) for the time period June 6, 2018 through November 28, 2023.

Genentech has recently discovered that Perjeta (pertuzumab) (NDC 50242-0145-01) had been inaccurately listed on the FDA Orphan Drug Website as having Orphan Drug Designation status. Based on our review, sole community hospitals (SCH), rural referral centers (RRC), critical access hospitals (CAH), and free standing cancer hospitals (CAN), may have made non-340B purchases of Perjeta that were eligible for 340B pricing during the time period June 6, 2018 through November 28, 2023, and therefore may be owed a refund.

If any such entity believes that it may be owed a refund, please send an email to Genentech_340B_Refund_Ops@gene.com with “Attention: 340B Perjeta Refund” in the subject line at its earliest convenience with the best contact information (email and phone number), the entity name(s) and the 340B ID(s), so that we may send a Refund Request Form and detailed information regarding the data we need to accurately calculate a refund, no later than September 30, 2024.

Genentech has asked the Office of Pharmacy Affairs ("OPA") to post this notice on OPA's public website to ensure transparency by providing access to information regarding Genentech's refund program to the public and specifically, to any affected 340B Covered Entity.